The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion

Exclusion Criteria

• •Diabetes
• •First-degree relatives with diabetes (both type 1 diabetes and type 2 diabetes)
• •Liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>2 times normal values) or history of hepatobiliary disorder
• •Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery
• •Reduced kidney function or nephropathy (estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria
• •Taking any kind of medicine on a regular basis
• •Intake of antibiotics two months prior to study
• •Active or recent malignant disease
• •Any treatment or condition requiring acute or sub-acute medical or surgical intervention
• •Any condition considered incompatible with participation by the investigators
• •If the subjects receive any antibiotic treatment while included in the study they will be excluded